Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Ly-2127399

Known as: LY2127399, LY3022859 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
PurposeLY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2016
2016
B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an… 
Review
2015
Review
2015
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical… 
  • figure 1
  • table 1
  • table 2
  • table 4
Review
2013
Review
2013
The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the… 
2013
2013
Background Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their… 
Review
2012
Review
2012
  • W. Stohl
  • Current Rheumatology Reports
  • 2012
  • Corpus ID: 42980394
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment… 
  • figure 1
  • table 1
2011
2011
8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY… 
Review
2011
Review
2011
Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology… 
  • figure 1
Review
2010
Review
2010
  • M. Buttmann
  • Expert review of neurotherapeutics
  • 2010
  • Corpus ID: 24588796
Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2…